A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Overview

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Work here?Claim your company

About Alnylam Pharmaceuticals

Simplify's Rating
Why Alnylam Pharmaceuticals is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Cambridge, MA

Founded

2002

Get referred to Alnylam Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • November 9, 2026 HELIOS-B data strengthened AMVUTTRA mortality and cardiovascular benefit claims.
  • November 4, 2026 board authorized a $1 billion buyback, signaling cash generation confidence.
  • Regeneron's November 2026 cemdisiran FDA decision and CIDEBsiRNA data expand royalty upside.

What critics are saying

  • October 29, 2026 Amvuttra slowdown triggered a 25% stock crash and securities probes.
  • Tolga Tanguler exits December 2026, exposing commercial execution failures during the Amvuttra reset.
  • 340B rule changes and restrictive Medicare Advantage policies threaten 2027 demand, pricing, and cash flow.

What makes Alnylam Pharmaceuticals unique

  • Alnylam owns first-mover RNAi leadership, with 2030 pipeline depth beyond Amvuttra.
  • Its AMVUTTRA franchise combines rare-disease pricing, chronic dosing, and expanding ATTR-CM evidence.
  • Regeneron partnership economics deliver royalties up to 20% on cemdisiran and CIDEBsiRNA.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$4.8B

Above

Industry Average

Funded Over

11 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Convertible Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Remote Work Options

Stock Price

Growth & Insights and Company News

6 month growth

10%

1 year growth

15%

2 year growth

30%
Associated Press
Nov 12th, 2026
Alnylam shares plunge 25% to $174 on slowing Amvuttra demand as Levi & Korsinsky opens investigation

Law firm Levi & Korsinsky is investigating potential securities law violations at Alnylam Pharmaceuticals (NASDAQ:ALNY), after the drugmaker's shares fell 25.13% on October 29, 2026. The stock closed at $174.00, a loss of $58.40 per share, after Alnylam reported slowing demand for Amvuttra. The treatment for transthyretin-mediated amyloidosis accounts for 87.5% of the company's product sales. US transthyretin demand growth was $81 million in the third quarter, down from $129 million in the previous quarter. The firm says investors who bought Alnylam shares and lost money can have their losses reviewed at no cost.

Regulatory Affairs Professionals Society
Nov 10th, 2026
Develop regulatory intelligence system before legal deadlines, experts say.

Develop regulatory intelligence system before legal deadlines, experts say. BARCELONA - Experts noted that companies shouldn't wait until a law is enacted to begin developing regulatory intelligence. Instead, they recommended that regulatory professionals engage with key stakeholders early to ensure they are prepared to implement the regulations and have a say in their implementation. Regulatory factors. Bertrand Fournier, senior director for regulatory policy at Alnylam Pharmaceuticals, spoke at the RAPS Regulatory Intelligence Conference, where he discussed several factors to consider when designing a sustainable regulatory intelligence system. He mentioned three external factors for regulatory professionals to consider: the complexity of the legislative and regulatory frameworks they must comply with, the evolving scientific and technological environment, and the political environment that influences regulatory practices. Fournier also said that regulatory affairs professionals need to consider their company's strategy in terms of potentially new regulatory regimes if they plan to expand the geographic scope of their business, and that the role of regulatory intelligence professionals is evolving. He noted that not only is there an overload of information and multiple layers of information sources, despite talk of international regulatory reliance, but many regulatory regimes are also pushing their own requirements, which is adding to the complexity of managing good regulatory intelligence. "It's important to note that we have seen in the past years some reliance or partnership initiatives here and there, like open access, but it seems to still be an exception to the rule," said Fournier. "Every region keeps on advocating for its own regulatory approval process, and this seems to be the goal. "Less reliance means more local legislation, more volume of legislation to process," he added. Fournier highlighted the EU Regulatory Intelligence Network Group's definition of regulatory intelligence, which states that regulatory intelligence is "The act of processing targeted information from multiple sources, analyzing data in its relevant context and generating a meaningful output - e.g. outlining risks and opportunities - to feed the regulatory strategy." Policy, intelligence, and compliance. Fournier said that while regulatory policy takes years to form and depends on how legislation is drafted and implemented, regulatory intelligence development occurs in the latter stages of legislation. As an example, he discussed the development of the EU New Pharmaceutical Legislation and noted that while the legislation began development back in 2023 with the EU Commission's proposal to create a new pharmaceutical framework, regulatory intelligence considerations about the framework weren't initiated until the EU Council amended the proposed legislation in 2025 and the tripartite agreement was reached later that year. Fournier highlighted that regulatory professionals responsible for compliance are also part of the consideration, but they don't really come into the picture until the law is enacted and guidelines are issued based on it. Fournier said the big takeaway is that companies should start developing a regulatory intelligence system based on the law before the final text is available. "It's a huge piece of legislation with a massive impact on most of the functions in our companies," said Fournier. "This means that we cannot just wait for the final text to be available in two weeks from now to start the implementation, to start the gap assessment, risk assessment, and implementation. "We are expecting more than 100 guidelines and implementing acts; there will be meetings, Q&As, and workshops. There is a wealth of information of interpretation data that will help us comply with this new regulation and directive that are going to be made available," he added. "Hence, the need for regulatory intelligence to be involved all along the way." Engage early. Katy Thompson, director for clinical trials regulatory at IQVIA in the United Kingdom, echoed Fournier and said it's important to start considering regulatory intelligence years before a law is implemented and guidance is in draft form. She emphasized that it is important to engage with stakeholders before regulatory requirements are finalized. "We can really start planning and engaging with industry bodies on the regulatory policy and what we would like to see change, and interpreting what is likely to come," said Thompson. Thompson also said that it's important to engage and plan for regulatory intelligence across departments, including quality assurance, legal, pharmacovigilance, and more. She noted that each function assesses the law's impact on its own processes, and the IT team should also be considered, as they will be crucial in building the tracking system that alerts regulatory professionals to key changes. "You need your solid database so people can extract the requirements, what documents are needed, what timelines apply... getting that information to the people," said Thompson. Ultimately, she said that all that information needs to be fed into the roadmap that translates early insights into a working regulatory plan. Roles and responsibilities Fournier also noted that the roles and responsibilities of regulatory professionals in developing the regulatory intelligence system and ensuring regulatory compliance will depend on their companies' size. When discussing how his own company is developing regulatory intelligence regarding the New Pharmaceutical Legislation, Fournier said their in-house regulatory professionals are already conducting gap analysis and impact assessments of the pre-adoption documents. He said they plan on redoing much of that work again when the final text is implemented in about two weeks' time. Fournier said that those responsible for regulatory intelligence need to work with their colleagues responsible for regulatory compliance, regulatory strategy, regulatory policy, and other regulatory affiliates. He noted that, depending on the company's size, such tasks may be consolidated under similar titles. Ultimately, Fournier said that the role of regulatory compliance in this situation is to assess internal regulatory processes, procedures, and systems in light of the proposed legislation. Similarly, the role of regulatory strategy is to assess the law's impact on product development; the role of regulatory policy is to inform the company's regulatory frameworks to ensure they are pragmatic and fit-for-purpose; and the other regulatory affiliates will provide guidance to determine alignment with other regulatory requirements and regional considerations. 10 Nov 2026 Acting US Food and Drug Administration (FDA) Commissioner Kyle Diamantas said there is significant public interest in its recently announced Expedited Investigational New Drug (IND) pilot at the Friends of Cancer Research (FOCR) annual meeting on Tuesday. 10 Nov 2026 Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

Los Angeles Biotechnology Network
Nov 6th, 2026
Chutes & Ladders - Novo's longtime CFO to hang up gloves as Galderma exec steps in.

Chutes & Ladders - Novo's longtime CFO to hang up gloves as Galderma exec steps in. Novo's CFO of the past 8 years is taking his leave at the end of the year. Alnylam is on the hunt for a new commercial chief amid news of Tolga Tanguler's departure. Amgen has looked within to replace its head of quality. Click here to view original post

Asianet News
Nov 2nd, 2026
FDA decision Watch: Regeneron and Roche's autoimmune drugs, Capricor's DMD therapy in spotlight.

FDA decision Watch: Regeneron and Roche's autoimmune drugs, Capricor's DMD therapy in spotlight. Published: Nov 02 2026, 05:15 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us November brings several closely watched FDA decisions, with Regeneron and its partner Alnylam's therapy for generalized myasthenia gravis and Roche's Gazyva for primary membranous nephropathy in the spotlight this week. * Regeneron and Alnylam's Cemdisiran showed significant improvements in daily functioning and muscle strength in a Phase 3 trial. * Alnylam could receive royalties of up to 15% of worldwide sales of Cemdisiran. * Roche awaits decisions on two drugs this month, including one for breast cancer. The U.S. Food and Drug Administration (FDA) is set to rule on several key drugs in the penultimate month of 2026, with Capricor Therapeutics' (CAPR) Deramiocel among the most closely watched decisions after the regulator extended its deadline by three months. Regeneron Pharmaceuticals (REGN) and its partner Alnylam Pharmaceuticals (ALNY), along with Roche (RHHBY), are also awaiting FDA decisions on their respective autoimmune disease treatments this month, although exact dates have not been disclosed. Regeneron and Alnylam await FDA decision on Cemdisiran. In June, the FDA granted Priority Review to Cemdisiran for generalized myasthenia gravis, an autoimmune disease that causes muscle weakness, with results expected any time this month. The Phase 3 Nimble trial testing the drug showed that patients receiving Cemdisiran experienced a 4.5-point improvement in daily functioning after 24 weeks, compared with 2.2 points for those receiving placebo. About 76.6% of Cemdisiran-treated patients achieved a clinically meaningful improvement of at least three points, compared with 44.1% in the placebo group. The treatment, administered through an injection once every three months, also met its secondary goal of improving muscle strength, with benefits observed by the second week of treatment. Regeneron is developing Cemdisiran under license from Alnylam, which could receive royalties of up to 15% of worldwide sales. Roche eyes two FDA decisions in November. Roche is awaiting FDA's decision on Gazyva for primary membranous nephropathy, a rare autoimmune disease that damages the kidneys and can eventually lead to kidney failure. The regulator granted Priority Review in July. The drug could become the first FDA-approved treatment specifically for the disease. In the Phase 3 MAJESTY trial involving 142 patients, 36.9% of Gazyva-treated patients achieved complete remission after two years, meeting the trial's primary and secondary goals. Separately, the FDA is also set to announce its decision on Roche's experimental breast cancer drug Giredestrant on November 30. The drug is being developed for patients with early-stage, estrogen receptor-positive, HER2-negative breast cancer. Roche sees peak annual sales exceeding CHF3 billion ($3.65 billion). How have RHHBY, ALNY and REGN stocks fared so far in 2026? Retail sentiment for RHHBY on Stocktwits remained 'bearish' over the past 24 hours, while sentiment for REGN remained 'extremely bullish' and 'bullish' for ALNY. Regeneron and Roche shares have gained 19.5% and 17.9% so far this year, respectively, while Alnylam Pharmaceuticals stock has slumped about 59%. Both Roche and Regeneron clocked their biggest monthly gains in October. ALNY shares have gained in just two months in 2026. Also read: Stocktwits Defense Watch: L3Harris, BA Report Record Backlogs, HII Raises FY2026 Shipbuilding Revenue Forecast (Exchange Rate: CHF1 = $1.22) Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Yahoo Finance
Nov 2nd, 2026
Alnylam stock falls 29.5% to $165: past 30% drops rose after a year only four of nine times

Alnylam Pharmaceuticals shares closed at $165 on October 30, 2026, down 29.5% from October 15. The stock lost 25.1% on October 29, when the company reported third-quarter results and management said it was not yet satisfied with demand growth. Revenue rose 16.7% to $1.46 billion, the slowest growth in five quarters. Product revenues grew 52%. Alnylam now expects 2026 sales of AMVUTTRA and ONPATTRO at the low end of its $4.2 billion to $4.5 billion range, as newer doctors are slow to change prescribing habits. Since 2010, the stock has fallen more than 30% over 30 trading days on nine earlier occasions. A year later, shares were higher in only four cases. Investors will watch 2027 product revenue guidance, due in February 2027.

Recently Posted Jobs

Sign up to get curated job recommendations

Alnylam Pharmaceuticals is Hiring for 111 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs